Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 98Carcinoma, Non-Small-Cell Lung 32Neoplasms 22Neoplasm Metastasis 14Carcinoma, Renal Cell 13Prostatic Neoplasms 12Lung Neoplasms 12Small Cell Lung Carcinoma 10Diabetes Mellitus, Insulin-Dependent, 12 10Pancreatic Neoplasms 7Uveal Melanoma 6Skin Neoplasms 6Ovarian Neoplasms 6Brain Neoplasms 6Advanced Cancer 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Mesothelioma 5Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Kidney Neoplasms 4Hodgkin Disease 4Head and Neck Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Merkel Cell 4Carcinoma, Hepatocellular 4Carcinoma 4Breast Neoplasms 4Various Advanced Cancer 3

Interventions

Sunitinib 3pembrolizumab 2pazopanib 2Axitinib 2aldesleukin 1Radiosurgery 1Nivolumab 1Nephrectomy 1Metastasectomy 1LY2510924 1Ipilimumab 1Interleukin-2 1Immunoglobulin G 1Cytoreduction Surgical Procedures 1Ascorbic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Clear-cell metastatic renal cell carcinoma × Ipilimumab × Clear all
NCT01472081 2021-12-02

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

Bristol-Myers Squibb

Phase 1 Completed
194 enrolled 18 charts
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡